Scynexis, Inc. · NASDAQ:SCYX
Scynexis — Corporate Update (January 2024)
14 slides from Scynexis's corporate update, Jan 5, 2024
Slide 1: A dynamic force in the fight against infectious disease
A dynamic force in the fight against infectious disease January 2024
Slide 2: Forward-Looking Statement
Forward-Looking Statement Certain statements regarding SCYNEXIS, Inc. (the “Company”) made in this presentation constitute forward-looking statements, including, but not limited to, statements regarding our business strategies and goals, plans and prospects, market size, adoption rate, potential rev
Slide 3: Scynexis Corporate Update – January 2024
Scynexis Corporate Update – January 2024 SCY-247 Update New promising pre-clinical data to be presented at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy January 25 – 27, 2024 Phase 1 study initiation planned for 2024 FURI / CARES / SCYNERGIA / VANQUISH /
Slide 4: Limited Antifungal Development Coupled With Escalating Resistance Has Resulted in Substantial Public Health Burden
Limited Antifungal Development Coupled With Escalating Resistance Has Resulted in Substantial Public Health Burden 1960 1970 1980 1990 2000 Emergence of Resistant Fungi Polyenes (amphotericin B) Azoles (Diflucan, Vfend) Echinocandins (Cancidas, Mycamine) Fungerps (BREXAFEMME) Echinocandin resistance
Slide 5: Fungal Resistance a Growing, Global, Public Health Threat
WHO Releases First-Ever List of Priority Deadly Fungal Pathogens CDC Identifies Drug Resistant Candida spp. and C. auris as Serious and Urgent Threats BARDA New Priority: Antifungals Fungal Resistance a Growing, Global, Public Health Threat Antifungal development is a well-recognized priority PASTEU
Slide 6: Fungerps are Well-Suited to Address High Priority Fungal Pathogens
Fungerps are Well-Suited to Address High Priority Fungal Pathogens 1. www.who.int/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi 2. GSK press briefing on SCYNEXIS/BREXAFEMME March 30, 2023 Demonstrated activity vs. fungi in both critical and high priority WHO Fungal Pr
Slide 7: Opportunities to Grow Shareholder Value
Opportunities to Grow Shareholder Value Advancing proprietary platform of triterpenoid fungerps while evaluating next generation innovations Maximize Ibrexafungerp opportunity Advance next generation fungerp Strengthened balance sheet enhances the opportunity to deliver additional innovative therapi
Slide 8: Ibrexafungerp GSK Licensing Agreement following December 2023 Amendment
Up to $35 million to be paid at each threshold of $750 million and $1 billion Ibrexafungerp GSK Licensing Agreement following December 2023 Amendment $72.35 million in development milestones tied to Ibrexafungerp development $49 million in regulatory approval milestones $57.5 million in commercial m
Slide 9: Fungerp Pipeline
Fungerp Pipeline *Partially Supported by NIH A New Class of Antifungals – Powerful - Different IBREXAFUNGERP VVC and Recurrent VVC Invasive Fungal Infections Candida auris infections* Phase 3 Phase 1 Phase 2 Approval Preclinical MARIO FURI / CARES (targeted completion in 1H 2024) SCY-247 IV & Oral O
Slide 10: SCY-247: Next Generation Fungerp
SCY-247: Next Generation Fungerp
Slide 11: SCY-247 – Our Next Generation Fungerp
SCY-247 – Our Next Generation Fungerp BROAD SPECTRUM OF ACTIVITY Fungicidal against Candida spp. Including Candida auris and other echinocandin-resistant Candida spp. Active against MDR pathogens Including azole-resistant Aspergillus spp. Other fungal pathogens Yeasts, molds, Pneumocystis and dimorp
Slide 12: SCY-247 – Our Next Generation Fungerp: Scientific Meeting Data
SCY-247 – Our Next Generation Fungerp 11th Congress on Trends in Medical Mycology (TIMM) - October 2023 Potent and broad-spectrum in vitro activity, including against a large array of yeasts, molds and dimorphic fungi Extensive tissue distribution in animal models Fungicidal activity against multi-d
Slide 13: SCY-247 – In Development Against Resistant Fungal Infections
SCY-247 – In Development Against Resistant Fungal Infections IP wholly owned by SCYNEXIS Development backed by NIH NIH provided ~$3M funding to Case Western University for development of SCY-247 against C. auris IND-enabling studies in progress Phase 1 study initiation anticipated in 2024 Anticipate
Slide 14: SCYNEXIS Strongly Positioned for Value Creation
SCYNEXIS Strongly Positioned for Value Creation Demonstrated internal expertise, solid supply chain and long IP protection, and potential for next generation products and partnerships Global urgency to rapidly develop potent antifungals to treat emerging infectious threats Strong Balance Sheet